Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Limited for allegedly making false and misleading statements regarding its business operations and prospects during the Class Period from February 21, 2025, to August 28, 2025 [3][7]. Allegation Details - The lawsuit claims that defendants materially overstated the progress of Telix's prostate cancer therapeutic candidates [3]. - It is alleged that the quality of Telix's supply chain and partners was also overstated [3]. - As a result of these misrepresentations, statements about Telix's business and operations were materially false and misleading, leading to investor damages when the true details emerged [3]. Next Steps - Investors who purchased Telix shares and suffered losses are encouraged to contact the law firm for more information or to discuss their rights [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is January 9, 2026 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5]. - The firm has offices in New York, California, and South Carolina, and specializes in commercial and securities litigation [5].
TELIX FINAL CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their Rights